Pronóstico del cáncer cérvico uterino estadios IIB-IIIB tratados con radio quimioterapia: experiencia Hospital Van Buren, Valparaíso, Chile

  • José Antonio Solís
  • Mónica Silva
  • Erasmo Bravo
  • Marielisa León
  • Guillermo Merino
  • Rodrigo Díaz
  • Christian Franck
  • Javier Egaña
  • Soledad Martínez
  • Karina Rosso

Resumen

Objetivo: analizar retrospectivamente resultados y factores pronósticos de pacientes con cáncer cérvico uterino estadios IIB-IIIB tratados con radioquimioterapia concomitante.

Materiales y métodos: desde septiembre 1999 a diciembre del 2002, 164 pacientes ingresaron con el diagnóstico de cáncer de cérvix, seleccionándose 83 en estadios IIB-IIIB, las que fueron tratadas con radioterapia y cisplatino semanal por cinco semanas.

Resultados: el 89,15% completó cinco ciclos de quimioterapia. La mediana de sobrevida global fue de 41 meses, con una sobrevida global (SG), sobrevida libre de enfermedad (SLE) y sobreviva libre de recurrencia loco-regional (SLRLR) a tres años de 68,8%, 66,3% y 83,1%, respectivamente. Factores pronósticos de sobrevida fueron etapa IIIB, diámetro tumoral clínico ≥ 7 cm, no realización de braquiterapia y enfermedad biparametrial.

Conclusiones: el tratamiento con radioterapia y quimioterapia concomitante con cisplatino en pacientes con cáncer cervicouterino estadios IIB-IIIB, es posible de realizar en el Hospital Carlos Van Buren perteneciente al sistema de salud público chileno, con buena tolerancia, resultados y factores pronósticos similares a los de la literatura internacional.

Descargas

La descarga de datos todavía no está disponible.

Biografía del autor/a

José Antonio Solís
Servicio de Oncología, Hospital Carlos Van Buren, Valparaíso, Chile. Cátedra de Oncología, Escuela de Medicina, Facultad de Medicina, Universidad de Valparaíso. Valparaíso, Chile. 
Mónica Silva
Servicio de Oncología, Hospital Carlos Van Buren, Valparaíso, Chile.
Erasmo Bravo
Servicio de Ginecología y Obstetricia, Hospital Carlos Van Buren, Valparaíso, Chile. Cátedra de Ginecología y Obstetricia, Escuela de Medicina, Facultad de Medicina, Universidad de Valparaíso, Valparaíso, Chile.
Marielisa León
 Servicio de Oncología, Hospital Carlos Van Buren, Valparaíso, Chile. Cátedra de Oncología, Escuela de Medicina, Facultad de Medicina, Universidad de Valparaíso. Valparaíso, Chile. 
Guillermo Merino
Servicio de Oncología, Hospital Carlos Van Buren, Valparaíso, Chile.
Rodrigo Díaz
Servicio de Oncología, Hospital Carlos Van Buren, Valparaíso, Chile.
Christian Franck
 Servicio de Ginecología y Obstetricia, Hospital Carlos Van Buren, Valparaíso, Chile. Cátedra de Ginecología y Obstetricia, Escuela de Medicina, Facultad de Medicina, Universidad de Valparaíso, Valparaíso, Chile.
Javier Egaña
Servicio de Ginecología y Obstetricia, Hospital Carlos Van Buren, Valparaíso, Chile. Cátedra de Ginecología y Obstetricia, Escuela de Medicina, Facultad de Medicina, Universidad de Valparaíso, Valparaíso, Chile.
Soledad Martínez
Alumno Interno, Escuela de Medicina, Facultad de Medicina, Universidad de Valparaíso, Valparaíso, Chile.
Karina Rosso
Alumno Interno, Escuela de Medicina, Facultad de Medicina, Universidad de Valparaíso, Valparaíso, Chile.

Referencias bibliográficas

Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.

Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64.

Stat bite: Cervical cancer mortality worldwide. J Natl Cancer Inst 2006;98:434.

National Cancer Institute. SEER Cancer Statistics Review, 1973-1996. http://www.seer.cancer.gov/csr/1973_1996/

Waggoner S. Cervical cancer. Lancet 2003;361:2217-25.

Ministerio de Salud de Chile, Programa Nacional de Cáncer. http://www.minsal.cl/ici/S_1%5CU_14/programa%20nacional%20de%20cancer.PDF

Barrillot I, Horiot JC, Pigneux J, Schraub S, Pourquier H, Daly N, et al. Carcinoma of the intact uterine cervix treated with radiotherapy alone: a French cooperative study: update and multivariate analysis of prognostic factors. Int J Radiat Oncol Biol Phys 1997;38:969-78.

Perez CA, Grigsby P, Nene S, Camel HM, Galakatos A, Kao MS, et al. Effect of tumor size on the prognosis of carcinoma of the uterine cervix treated with irradiation alone. Cancer 1992;69:2796-806.

Perez CA, Grigsby PW, Chao KS, Mutch DG, Lockett MA. Tumor size irradiation dose, and long-term outcome of carcinoma of uterine cervix. Int J Radiat Oncol Biol Phys 1998;41:307-17.

Lanciano RM, Won M, Coia LR, Hanks GE. Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: a final report of the 1973 and 1978 patterns of care studies. Int J Radiat Oncol Biol Phys 1991;20:667-76.

Fletcher GH. Clinical dose-response curves of human malignant epithelial tumours. Br J Radiol 1973;46:1-12.

Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-53.

Whitney CW, Sause W, Bundy BN, Malfetano JH,Hannigan EV, Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjuvant to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group Study. J Clin Oncol 1999;17:1339-48.

Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggis CL 3rd, et al. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154-61.

Eifel P, Winter K, Morris M, Levenback C, Grigsby P, Cooper J, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 2004;22:872-80.

Morris M, Eifel P, Lu J, Grigsby P, Levenback C, Stevens R, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-43.

Peters WA 3rd, Liu PY, Barret RJ 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high risk early stage cancer of the cervix. J Clin Oncol 2000;18:1606-13.

Pearcey R, Brundage M, Drovin P, Jeffrey J, Johnston D, Lukka H, et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 2002;20:966-72.

Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001;358:781-6.

Lukka H, Hirte H, Fyles A, Thomas G, Elit L, Johnston M, et al. Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer --a meta-analysis. Clin Oncol 2002;14:203-12.

NCI Issues Clinical Announcement on Cervical Cancer: Chemotherapy Plus Radiation Improves Survival. http://www.cancer.gov/newscenter/cervicalcancer.

Rose PG, Lappas PT. Analysis of the cost effectiveness of concurrent cisplatin-based chemoradiation in cervical cancer: Implications from five randomized trials. Gynecol Oncol 2000;78:3-6.

American Joint Committee on Cancer. AJCC: Cancer Staging Manual, Sixth Edition. Editorial Springer; 2002. p. 267-73.

Cox JD, Stetz J, Pajaj TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-6.

Kaplan EL, Meir P. Nonparametric estimation for incomplete obser vations. J Am Stat Assoc 1958;53:457-81.

Mantel N, Haenzel W. Chi-square test with one-degree of freedom extensions of Mantel-Haenzel procedure. J Am Stat Assoc 1963;58:690-700.

Lanciano R, Calkins A, Bundy BN, Parham G, Lucci JA 3rd, Moore D, et al. Randomized comparison of weekly cisplatin or protracted venous infusion of fluoracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study. J Clin Oncol 2005;23:8289-95.

San Martín R, Suárez E, Olfos P, Escudero P, Rojas L, Larraguibel P, et al. Cáncer cervicouterino en estadio IB2: tratamiento con radioquimioterapia concomitante y cirugía. Rev Chil Obstet Ginecol 2003;68:447-57.

Kirwan JM, Symonds P, Green JA, Tierney J, Collingwood M, Williams C. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol 2003;68:217-26.

Cetina L, Rivera L, Hinojosa J, Poitevin A, Uribe J, López-Graniel C, et al. Routine management of locally advanced cervical cancer with concurrent radiation and cisplatin. Five-year results. BMC Womens Health 2006;6:3.

Lanciano RM, Martz K, Coia LR, Hanks GE. Tumor and treatment factors improving outcome in stage III-B cervix cancer. Int J Radiat Oncol Biol Phys 1991;20:95-100.

Kovalic JL, Perez CA, Grigsby PW, Lockett MA. The effect of volume of disease in patients with carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1991;21:905-10.

Stehman FB, Bundy BN, DiSaia PJ, Keys HM, Larson JE, Fowler WC. Carcinoma of the cervix treated with radiation therapy: I. A multivariate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer 1991;67:2776-85.

Eifel PJ, Morris M, Wharton JT, Oswald MJ. The Influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1994;29:9-16.

League of Nations Health Organization inquiry into the results of radiotherapy in cancer of the uterus. Atlas illustrating the division of cancer of the uterine cervix into four stages according to the anatomo-clinical extent of growth. Stockholm: Kungl-Boktryckeriet P.A. Norstedt & Sener; 1938.

International Federation of Gynecology and Obstetrics. Staging announcement: FIGO staging of gynecologic cancers: cervical and vulva. Int J Gynecol Cancer 1995;5:319.

Hricak H, Lacey C, Sandles LG, Chang YC, Winkler ML, Stern JL. Invasive cervical carcinoma: comparison of MR imaging and surgical findings. Radiology 1988;166:623-31.

Miller T, Grigsby P. Measurements of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys 2002;53:353-9.

Logsdon MD, Eifel PJ. FIGO IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy. Int J Radiat Oncol Biol Phys 1999;43:763-75.

Saibishkumar EP, Patel FD, Sharma SC, Karunanidhi G, Ghoshal S, Kumar V, et al. prognostic value of response to external radiation in stage IIIB cancer cervix in predicting clinical outcomes: a retrospective analysis of 556 patients from India. Radiother Oncol 2006;79:142-6.

Higgins RV, Naumann WR, Hall JB, Haake M. Concurrent carboplatin with pelvic radiation therapy in the primary treatment of cervix cancer. Gynecol Oncol 2003;89:499-503.

Dubay RA, Rose PG, O´Malley DM, Shalodi AD, Ludin A, Selim M. Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer. Gynecol Oncol 2004;94:121-4.

Lor vidhaya V, Chitapanar ux I, Sangruchi S, Lertsanguansinchai P, Kongthanarat Y, Tangkaratt S, et al. Concurrent mitomycin C, 5-fluoracil and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial. Int J Radiat Oncol Biol Phys 2003;55:1226-32.

Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005;23:4626-33.

Mundt AJ, Roeske JC, Lujan AE, Yamada SD, Waggoner SE, Fleming G, et al. initial clinical experience with intensity-modulated whole pelvis radiation therapy in women with gynecologic malignancies. Gynecol Oncol 2001;82:456-63.

Portelance L, Chao KS, Grigsby PW, Bennet H, Low D. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. Int J Radiat Oncol Biol Phys 2001;51:261-6.

Mundt AJ, Lujan AE, Rotmensh J, Waggoner SE, Yamada SD, Fleming G, et al. Intensity modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2002;52:1330-7.

Brixey CJ, Roeske JC, Lujan AE, Yamada SD, Rotmensh J, Mundt AJ, et al. Impact of intensity modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2002;54:1388-96.

Gertzen K, Colonello K, Heron DE, Lalonde RJ, Fitian ID, Comerci JT, et al. Feasibility of concurrent cisplatin and extended field radiation therapy (EFRT) using intensity-modulated radiotherapy (IMRT) for carcinoma of the cervix. Gynecol Oncol 2006;102:182-8.

Publicado
2007-12-20
Cómo citar
1.
Solís JA, Silva M, Bravo E, León M, Merino G, Díaz R, Franck C, Egaña J, Martínez S, Rosso K. Pronóstico del cáncer cérvico uterino estadios IIB-IIIB tratados con radio quimioterapia: experiencia Hospital Van Buren, Valparaíso, Chile. Rev. Colomb. Obstet. Ginecol. [Internet]. 20 de diciembre de 2007 [citado 21 de septiembre de 2021];58(4):268-76. Disponible en: https://revista.fecolsog.org/index.php/rcog/article/view/436
Sección
Investigación Original
Crossref Cited-by logo